在2000年至2022年的瑞典队列中,HPV16型阳性和其他高风险HPV型阳性口腔状细胞癌的年龄和瘤呈现不同
Anders Näsman1,2, Madeleine Birgersson1, Tobias Näsman1,2
1Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
International journal of cancer
|August 29, 2025
概括
人类乳头瘤病毒阳性口腔状细胞癌 (HPV+ OPSCC) 患者年轻,HPV16阳性病例比其他高风险HPV类型年轻. 这种年龄差异在近年来更加明显.
科学领域:
- 癌症学
- 病毒学
- 流行病学
背景情况:
- 人类乳头瘤病毒阳性口腔状细胞癌 (HPV+ OPSCC) 的发生率有所增加,HPV 16型 (HPV16) 在历史上占主导地位.
- 之前的发现表明HPV+ OPSCC患者的年龄比HPV阴性 (HPV-) 患者更小,预后更好.
- 最近的趋势表明年龄差异正在减少,其他高风险HPV类型 (HR-HPV) 也在增加.
研究的目的:
- 调查HPV16阳性OPSCC患者与其他HR-HPV型阳性OPSCC患者的年龄差异.
- 在OPSCC中分析与不同HR-HPV类型相关的人口和临床特征.
主要方法:
- 在瑞典斯德哥尔摩-戈特兰地区对1681名OPSCC患者的回顾性分析 (2000-2022年).
- 检测常见的粘膜HPV类型,将感染分为HPV16,其他HR-HPV,低风险HPV和HPV阴性.
- 在HPV亚组之间对年龄,性别和瘤特征进行统计比较.
主要成果:
- 与HPV- OPSCC患者相比,HPV+ OPSCC患者的年龄明显较小 (平均为63岁).
- 在HPV+ OPSCC中,HPV16阳性患者 (平均61.1岁) 比其他HR-HPV阳性患者 (平均64.5岁) 年轻得多.
- 最近几年 (2010-2022) 的HPV16阳性OPSCC患者呈现较小的瘤和显著的年龄差异.
结论:
- 在HPV16阳性和其他HR-HPV型阳性OPSCC之间存在显著的年龄差异,特别是在最近几年.
- 在OPSCC中,超出HPV16的HR-HPV类型的流行率越来越高,因此需要进一步调查.
- 这些发现突显了HPV驱动的口腔癌的流行病学模式.
相关概念视频
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Cancers Originate from Somatic Mutations in a Single Cell
12.7K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.7K
Rous Sarcoma Virus (RSV) and Cancer
5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.4K
Prevalence and Incidence
790
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
790
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


